Delivering on the promise of science by advancing next‑generation PBD‑based ADCs
ADC Therapeutics is advancing next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. These proprietary PBD‑based ADCs are expected to provide a novel way to treat hematologic cancers and solid tumors, address significant unmet medical needs, and improve the lives of patients with cancer.
Advancing antibody drug conjugates with PBD-dimer technology
The antigen-targeted antibody binds to a specific tumor cell surface antigen and internalizes the drug conjugate.
The potent PBD dimer is released inside the cell, where it then creates a covalent cross-link between the strands of the DNA double helix.
Because these cross-links do not trigger DNA repair, they are invisible to repair mechanisms and can covertly persist to interrupt cell division and cause tumor cell death.
A novel class of PBD dimers
ADC Therapeutics’ proprietary ADCs are highly targeted drug constructs that combine monoclonal antibodies specific to surface tumor targets with a novel class of highly potent PBD dimer toxins.
Less visible to DNA repair mechanisms
After the antibody binds to a specific tumor cell surface antigen and the ADC is internalized, the cytotoxic PBD dimer is designed to be released inside the cells where it binds in the minor groove of double-helix DNA, forming potent cytotoxic DNA interstrand cross-links. The cross-links formed by the PBD dimer are designed to block cell division and kill the cancer cells. PBD dimers do not distort the DNA structure, which makes them invisible to repair mechanisms and allows the cross-links to persist within the DNA.
Designed for reduced drug resistance
Unlike earlier generation PBD chemistry, these proprietary PBD dimers are not a substrate for multi-drug resistance proteins—even in hard-to-treat tumors.